Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | ESR1 | P03372 | 7/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 2/20 | 0.41 |
| ▸ | CASP7 | P55210 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14185178 | 0.89 | CA12 (0.52) | CA12CA9CA1CA2ESR1 | |
| SCHEMBL14185180 | 0.86 | CA12 (0.50) | CA12CA9CA1CA2ESR1 | |
| SCHEMBL14185188 | 0.86 | CA12 (0.50) | CA12CA9CA1CA2ESR1 | |
| SCHEMBL14185231 | 0.80 | CA12 (0.46) | CA12CA9CA1CA2ESR1 | |
| SCHEMBL14185206 | 0.78 | ESR1 (0.62) | ESR1ESR2KDM4EALDH1A1MEN1 | |
| SCHEMBL14185227 | 0.76 | ESR1 (0.59) | ESR1ESR2KDM4EALDH1A1MEN1 | |
| SCHEMBL29036844 | 0.76 | CA12 (0.59) | CA12CA9CA1CA2ESR1 | |
| SCHEMBL14185210 | 0.75 | ESR1 (0.50) | ESR1ESR2KDM4EALDH1A1MEN1 | |
| SCHEMBL14185243 | 0.74 | ALDH1A1 (0.75) | CA12CA9CA1CA2ESR1 | |
| SCHEMBL11013724 | 0.74 | KDM4E (0.60) | CA12CA9CA1CA2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080114056-A1 | Chromone Derivatives Useful as Vanilloid Antagonists | NOVARTIS AG (CH) | 2008-05-15 | — | — | US | disclosed |
| US-20080114056-A1 | Chromone Derivatives Useful as Vanilloid Antagonists | NOVARTIS AG (CH) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114056-A1 | Chromone Derivatives Useful as Vanilloid Antagonists | TRPV1, CHRM3, TRPV3 | CA12 1499/4885CA9 1277/4885CA1 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.